Top

Published in:

Open Access 01-04-2021 | Azathioprine | Guidelines

The Asian Pacific Association for the Study of the Liver clinical practice guidance: the diagnosis and management of patients with autoimmune hepatitis

Authors: Guiqiang Wang, Atsushi Tanaka, Hong Zhao, Jidong Jia, Xiong Ma, Kenichi Harada, Fu-Sheng Wang, Lai Wei, Qixia Wang, Ying Sun, Yuan Hong, Huiying Rao, Cumali Efe, George Lau, Diana Payawal, Rino Gani, Keith Lindor, Wasim Jafri, Masao Omata, Shiv Kumar Sarin

Published in: Hepatology International | Issue 2/2021

Excerpt

Autoimmune hepatitis (AIH) is not a common disease but with increasing incidence in Asia–Pacific area. Although the etiology and pathogenesis are not completely clear, the disease is the result of loss of autoimmune tolerance in genetically predisposed individuals. AIH is characterized by autoantibodies, hypergammaglobulinemia, and interface hepatitis. Corticosteroids and azathioprine are standard regimens for AIH, which should be started after diagnosis. Alternative therapy should be considered for those who do not respond to standard regimens. End-stage AIH patient could be saved by liver transplantation. …

Yang F, Wang Q, Bian Z, Ren LL, Jia J, Ma X. Autoimmune hepatitis: east meets west. J Gastroenterol Hepatol 2015;30(8):1230–1236PubMedCrossRef

Lv T, Li M, Zeng N, Zhang J, Li S, Chen S, et al. Systematic review and meta-analysis on the incidence and prevalence of autoimmune hepatitis in Asian, European, and American population. J Gastroenterol Hepatol 2019;34(10):1676–1684PubMedCrossRef

Wong RJ, Gish R, Frederick T, Bzowej N, Frenette C. The impact of race/ethnicity on the clinical epidemiology of autoimmune hepatitis. J Clin Gastroenterol 2012;46(2):155–161PubMedCrossRef

Tanaka A, Ma X, Yokosuka O, Weltman M, You H, Amarapurkar DN, et al. Autoimmune liver diseases in the Asia-Pacific region: proceedings of APASL symposium on AIH and PBC 2016. Hepatol Int 2016;10(6):909–915PubMedCrossRef

Tanaka A, Mori M, Matsumoto K, Ohira H, Tazuma S, Takikawa H. Increase trend in the prevalence and male-to-female ratio of primary biliary cholangitis, autoimmune hepatitis, and primary sclerosing cholangitis in Japan. Hepatol Res 2019;49(8):881–889.PubMedCrossRef

Kim BH, Choi HY, Ki M, Kim KA, Jang ES, Jeong SH. Population-based prevalence, incidence, and disease burden of autoimmune hepatitis in south Korea. PLoS ONE 2017;12(8):e0182391PubMedPubMedCentralCrossRef

Ngu JH, Bechly K, Chapman BA, Burt MJ, Barclay ML, Gearry RB, et al. Population-based epidemiology study of autoimmune hepatitis: a disease of older women? J Gastroenterol Hepatol 2010;25(10):1681–1686PubMedCrossRef

Valgeirsson KB, Hreinsson JP, Bjornsson ES. Increased incidence of autoimmune hepatitis is associated with wider use of biological drugs. Liver Int 2019;39(12):2341–2349PubMedCrossRef

Mells GF, Kaser A, Karlsen TH. Novel insights into autoimmune liver diseases provided by genome-wide association studies. J Autoimmun 2013;46:41–54PubMedCrossRef

10.

Werner M, Prytz H, Ohlsson B, Almer S, Bjornsson E, Bergquist A, et al. Epidemiology and the initial presentation of autoimmune hepatitis in Sweden: a nationwide study. Scand J Gastroenterol 2008;43(10):1232–1240PubMedCrossRef

11.

Wang Q, Yang F, Miao Q, Krawitt EL, Gershwin ME, Ma X. The clinical phenotypes of autoimmune hepatitis: a comprehensive review. J Autoimmun 2016;66:98–107PubMedCrossRef

12.

EASL. EASL clinical practice guidelines: autoimmune hepatitis. J Hepatol 2015;63(4):971–1004CrossRef

13.

Floreani A, Restrepo-Jimenez P, Secchi MF, De Martin S, Leung PSC, Krawitt E, et al. Etiopathogenesis of autoimmune hepatitis. J Autoimmun 2018;95:133–143PubMedCrossRef

14.

Umemura T, Katsuyama Y, Yoshizawa K, Kimura T, Joshita S, Komatsu M, et al. Human leukocyte antigen class II haplotypes affect clinical characteristics and progression of type 1 autoimmune hepatitis in Japan. PLoS ONE 2014;9(6):e100565PubMedPubMedCentralCrossRef

15.

Oka S, Furukawa H, Yasunami M, Kawasaki A, Nakamura H, Nakamura M, et al. HLA-DRB1 and DQB1 alleles in Japanese type 1 autoimmune hepatitis: the predisposing role of the DR4/DR8 heterozygous genotype. PLoS ONE 2017;12(10):e0187325PubMedPubMedCentralCrossRef

16.

Amarapurkar DN, Patel ND, Amarapurkar AD, Kankonkar SR. HLA genotyping in type-I autoimmune hepatitis in western India. J Assoc Physicians India 2003;51:967–969PubMed

17.

Kaur N, Minz RW, Anand S, Saikia B, Aggarwal R, Das A, et al. HLA DRB1 alleles discriminate the manifestation of autoimmune hepatitis as type 1 or type 2 in north Indian population. J Clin Exp Hepatol 2014;4(1):14–18PubMedCrossRef

18.

Hiraide A, Imazeki F, Yokosuka O, Kanda T, Kojima H, Fukai K, et al. Fas polymorphisms influence susceptibility to autoimmune hepatitis. Am J Gastroenterol 2005;100(6):1322–1329PubMedCrossRef

19.

Umemura T, Joshita S, Yamazaki T, Komatsu M, Katsuyama Y, Yoshizawa K, et al. Genetic association of PTPN22 polymorphisms with autoimmune hepatitis and primary biliary cholangitis in Japan. Sci Rep 2016;6:29770PubMedPubMedCentralCrossRef

20.

Fan L, Tu X, Zhu Y, Zhou L, Pfeiffer T, Feltens R, et al. Genetic association of vitamin D receptor polymorphisms with autoimmune hepatitis and primary biliary cirrhosis in the Chinese. J Gastroenterol Hepatol 2005;20(2):249–255PubMedCrossRef

21.

de Boer YS, van Gerven NM, Zwiers A, Verwer BJ, van Hoek B, van Erpecum KJ, et al. Genome-wide association study identifies variants associated with autoimmune hepatitis type 1. Gastroenterology 2014;147(2):443-452.e5PubMedCrossRef

22.

Webb GJ, Hirschfield GM. Using GWAS to identify genetic predisposition in hepatic autoimmunity. J Autoimmun 2016;66:25–39PubMedCrossRef

23.

Seki T, Ota M, Furuta S, Fukushima H, Kondo T, Hino K, et al. HLA class II molecules and autoimmune hepatitis susceptibility in Japanese patients. Gastroenterology 1992;103(3):1041–1047PubMedCrossRef

24.

Strettell MD, Donaldson PT, Thomson LJ, Santrach PJ, Moore SB, Czaja AJ, et al. Allelic basis for HLA-encoded susceptibility to type 1 autoimmune hepatitis. Gastroenterology 1997;112(6):2028–2035PubMedCrossRef

25.

Czaja AJ, Strettell MD, Thomson LJ, Santrach PJ, Moore SB, Donaldson PT, et al. Associations between alleles of the major histocompatibility complex and type 1 autoimmune hepatitis. Hepatology 1997;25(2):317–323PubMedCrossRef

26.

Vazquez-Garcia MN, Alaez C, Olivo A, Debaz H, Perez-Luque E, Burguete A, et al. MHC class II sequences of susceptibility and protection in Mexicans with autoimmune hepatitis. J Hepatol 1998;28(6):985–990PubMedCrossRef

27.

Bittencourt PL, Goldberg AC, Cancado EL, Porta G, Carrilho FJ, Farias AQ, et al. Genetic heterogeneity in susceptibility to autoimmune hepatitis types 1 and 2. Am J Gastroenterol 1999;94(7):1906–1913PubMedCrossRef

28.

Muratori P, Czaja AJ, Muratori L, Pappas G, Maccariello S, Cassani F, et al. Genetic distinctions between autoimmune hepatitis in Italy and north America. World J Gastroenterol 2005;11(12):1862–1866PubMedPubMedCentralCrossRef

29.

Teufel A, Worns M, Weinmann A, Centner C, Piendl A, Lohse AW, et al. Genetic association of autoimmune hepatitis and human leucocyte antigen in German patients. World J Gastroenterol 2006;12(34):5513–5516PubMedPubMedCentralCrossRef

30.

Al-Chalabi T, Boccato S, Portmann BC, McFarlane IG, Heneghan MA. Autoimmune hepatitis (AIH) in the elderly: a systematic retrospective analysis of a large group of consecutive patients with definite AIH followed at a tertiary referral centre. J Hepatol 2006;45(4):575–583PubMedCrossRef

31.

Djilali-Saiah I, Fakhfakh A, Louafi H, Caillat-Zucman S, Debray D, Alvarez F. HLA class II influences humoral autoimmunity in patients with type 2 autoimmune hepatitis. J Hepatol 2006;45(6):844–850PubMedCrossRef

32.

Mdel PF, Machado IV, Gil G, Fernandez-Mestre M, Dagher L, Leon RV, et al. Genetic contribution of major histocompatibility complex class II region to type 1 autoimmune hepatitis susceptibility in Venezuela. Liver Int 2007;27(10):1409–1416CrossRef

33.

Lim YS, Oh HB, Choi SE, Kwon OJ, Heo YS, Lee HC, et al. Susceptibility to type 1 autoimmune hepatitis is associated with shared amino acid sequences at positions 70–74 of the HLA-DRB1 molecule. J Hepatol 2008;48(1):133–139PubMedCrossRef

34.

Czaja AJ. Transitioning from idiopathic to explainable autoimmune hepatitis. Dig Dis Sci 2015;60(10):2881–2900PubMedCrossRef

35.

Christen U, Hintermann E. Pathogen infection as a possible cause for autoimmune hepatitis. Int Rev Immunol 2014;33(4):296–313PubMedCrossRef

36.

Gatselis NK, Zachou K, Koukoulis GK, Dalekos GN. Autoimmune hepatitis, one disease with many faces: etiopathogenetic, clinico-laboratory and histological characteristics. World J Gastroenterol 2015;21(1):60–83PubMedPubMedCentralCrossRef

37.

Efe C, Kav T, Aydin C, Cengiz M, Imga NN, Purnak T, et al. Low serum vitamin D levels are associated with severe histological features and poor response to therapy in patients with autoimmune hepatitis. Dig Dis Sci 2014;59(12):3035–3042PubMedCrossRef

38.

Albert LJ, Inman RD. Molecular mimicry and autoimmunity. N Engl J Med 1999;341(27):2068–2074PubMedCrossRef

39.

Gleeson D, Heneghan MA, British Society of Gastroenterology. British Society of Gastroenterology (BSG) guidelines for management of autoimmune hepatitis. Gut 2011;60(12):1611–1629PubMedCrossRef

40.

Czaja AJ. Drug-induced autoimmune-like hepatitis. Dig Dis Sci. 2011;56(4):958–976.PubMedCrossRef

41.

Czaja AJ. Autoimmune hepatitis. Part A: pathogenesis. Expert Rev Gastroenterol Hepatol 2007;1(1):113–128PubMedCrossRef

42.

Mieli-Vergani G, Vergani D, Czaja AJ, Manns MP, Krawitt EL, Vierling JM, et al. Autoimmune hepatitis. Nat Rev Dis Primers 2018;4:18017PubMedCrossRef

43.

Lin R, Zhou L, Zhang J, Wang B. Abnormal intestinal permeability and microbiota in patients with autoimmune hepatitis. Int J Clin Exp Pathol 2015;8(5):5153–5160PubMedPubMedCentral

44.

Vieira SM, Hiltensperger M, Kumar V, Zegarra-Ruiz D, Dehner C, Khan N, et al. Translocation of a gut pathobiont drives autoimmunity in mice and humans. Science 2018;359(6380):1156–1161PubMedCentralCrossRef

45.

Wei Y, Li Y, Yan L, Sun C, Miao Q, Wang Q, et al. Alterations of gut microbiome in autoimmune hepatitis. Gut 2020;69(3):569–577PubMedCrossRef

46.

Longhi MS, Ma Y, Bogdanos DP, Cheeseman P, Mieli-Vergani G, Vergani D. Impairment of CD4(+)CD25(+) regulatory T-cells in autoimmune liver disease. J Hepatol 2004;41(1):31–37PubMedCrossRef

47.

Longhi MS, Ma Y, Mitry RR, Bogdanos DP, Heneghan M, Cheeseman P, et al. Effect of CD4+ CD25+ regulatory T-cells on CD8 T-cell function in patients with autoimmune hepatitis. J Autoimmun 2005;25(1):63–71PubMedCrossRef

48.

Longhi MS, Hussain MJ, Mitry RR, Arora SK, Mieli-Vergani G, Vergani D, et al. Functional study of CD4+CD25+ regulatory T cells in health and autoimmune hepatitis. J Immunol 2006;176(7):4484–4491PubMedCrossRef

49.

Ferri S, Longhi MS, De Molo C, Lalanne C, Muratori P, Granito A, et al. A multifaceted imbalance of T cells with regulatory function characterizes type 1 autoimmune hepatitis. Hepatology 2010;52(3):999–1007PubMedCrossRef

50.

Zhao L, Tang Y, You Z, Wang Q, Liang S, Han X, et al. Interleukin-17 contributes to the pathogenesis of autoimmune hepatitis through inducing hepatic interleukin-6 expression. PLoS ONE 2011;6(4):e18909PubMedPubMedCentralCrossRef

51.

Zhang H, Liu Y, Bian Z, Huang S, Han X, You Z, et al. The critical role of myeloid-derived suppressor cells and FXR activation in immune-mediated liver injury. J Autoimmun 2014;53:55–66PubMedCrossRef

52.

Feld JJ, Dinh H, Arenovich T, Marcus VA, Wanless IR, Heathcote EJ. Autoimmune hepatitis: effect of symptoms and cirrhosis on natural history and outcome. Hepatology 2005;42(1):53–62PubMedCrossRef

53.

Kogan J, Safadi R, Ashur Y, Shouval D, Ilan Y. Prognosis of symptomatic versus asymptomatic autoimmune hepatitis: a study of 68 patients. J Clin Gastroenterol 2002;35(1):75–81PubMedCrossRef

54.

Czaja AJ. Diverse manifestations and evolving treatments of autoimmune hepatitis. Minerva Gastroenterol Dietol 2005;51(4):313–333PubMed

55.

Krawitt EL. Autoimmune hepatitis. N Engl J Med 2006;354(1):54–66PubMedCrossRef

56.

Czaja AJ, Manns MP. Advances in the diagnosis, pathogenesis, and management of autoimmune hepatitis. Gastroenterology 2010;139(1):58-72.e4PubMedCrossRef

57.

Liberal R, Grant CR, Mieli-Vergani G, Vergani D. Autoimmune hepatitis: a comprehensive review. J Autoimmun 2013;41:126–139PubMedCrossRef

58.

Yamamoto K, Miyake Y, Ohira H, Suzuki Y, Zeniya M, Onji M, et al. Prognosis of autoimmune hepatitis showing acute presentation. Hepatol Res 2013;43(6):630–638PubMedCrossRef

59.

Joshita S, Yoshizawa K, Umemura T, Ohira H, Takahashi A, Harada K, et al. Clinical features of autoimmune hepatitis with acute presentation: a Japanese nationwide survey. J Gastroenterol 2018;53(9):1079–1088PubMedCrossRef

60.

Abe M, Mashiba T, Zeniya M, Yamamoto K, Onji M, Tsubouchi H, et al. Present status of autoimmune hepatitis in Japan: a nationwide survey. J Gastroenterol 2011;46(9):1136–1141PubMedCrossRef

61.

Miyake Y, Iwasaki Y, Kobashi H, Yasunaka T, Ikeda F, Takaki A, et al. Autoimmune hepatitis with acute presentation in Japan. Dig Liver Dis 2010;42(1):51–54PubMedCrossRef

62.

Anand L, Choudhury A, Bihari C, Sharma BC, Kumar M, Maiwall R, et al. Flare of autoimmune hepatitis causing acute on chronic liver failure (ACLF): diagnosis and response to corticosteroid therapy. Hepatology 2019;70(2):587–596. https://doi.org/10.1002/hep.30205CrossRef

63.

Iwai M, Jo M, Ishii M, Mori T, Harada Y. Comparison of clinical features and liver histology in acute and chronic autoimmune hepatitis. Hepatol Res 2008;38(8):784–789PubMedCrossRef

64.

Weiler-Normann C, Lohse AW. Acute autoimmune hepatitis: many open questions. J Hepatol 2014;61(4):727–729PubMedCrossRef

65.

Dalekos GN, Gatselis NK, Zachou K. Acute severe autoimmune hepatitis: corticosteroids or liver transplantation? Liver Transpl 2019;25(10):1588–1589PubMedCrossRef

66.

Manns MP, Czaja AJ, Gorham JD, Krawitt EL, Mieli-Vergani G, Vergani D, et al. Diagnosis and management of autoimmune hepatitis. Hepatology 2010;51(6):2193–2213PubMedCrossRef

67.

Miyake Y, Iwasaki Y, Terada R, Nagano T, Kobashi H, Sakaguchi K, et al. A model for estimating cirrhosis in patients with type 1 autoimmune hepatitis. Hepatol Res 2008;38(7):658–663PubMedCrossRef

68.

Abe K, Katsushima F, Kanno Y, Takahashi A, Yokokawa J, Ohira H, et al. Clinical features of cirrhosis in Japanese patients with type I autoimmune hepatitis. Intern Med 2012;51(24):3323–3328PubMedCrossRef

69.

Zachou K, Muratori P, Koukoulis GK, Granito A, Gatselis N, Fabbri A, et al. Review article: autoimmune hepatitis—current management and challenges. Aliment Pharmacol Ther 2013;38(8):887–913PubMedCrossRef

70.

Yeoman AD, Al-Chalabi T, Karani JB, Quaglia A, Devlin J, Mieli-Vergani G, et al. Evaluation of risk factors in the development of hepatocellular carcinoma in autoimmune hepatitis: implications for follow-up and screening. Hepatology 2008;48(3):863–870PubMedCrossRef

71.

Johnson PJ, McFarlane IG, OBotP Convenors. Meeting report: International autoimmune hepatitis group. Hepatology 1993;18(4):998–1005PubMedCrossRef

72.

Alvarez F, Berg PA, Bianchi FB, Bianchi L, Burroughs AK, Cancado EL, et al. International autoimmune hepatitis group report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol 1999;31(5):929–938PubMedCrossRef

73.

Hennes EM, Zeniya M, Czaja AJ, Parés A, Dalekos GN, Krawitt EL, et al. Simplified criteria for the diagnosis of autoimmune hepatitis. Hepatology 2008;48(1):169–176PubMedCrossRef

74.

The French METAVIR Cooperative Study Group. Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. Hepatology 1994;20(1 Pt 1):15–20CrossRef

75.

Rastogi A, Kumar A, Sakhuja P, Bihari C, Gondal R, Hissar S, et al. Liver histology as predictor of outcome in patients with acute-on-chronic liver failure (ACLF). Virchows Arch 2011;459(2):121–127PubMedCrossRef

76.

Kirstein MM, Metzler F, Geiger E, Heinrich E, Hallensleben M, Manns MP, et al. Prediction of short- and long-term outcome in patients with autoimmune hepatitis. Hepatology 2015;62(5):1524–1535PubMedCrossRef

77.

Muratori P, Lalanne C, Bianchi G, Lenzi M, Muratori L. Predictive factors of poor response to therapy in autoimmune hepatitis. Dig Liver Dis 2016;48(9):1078–1081PubMedCrossRef

78.

Czaja AJ, Carpenter HA. Histological features associated with relapse after corticosteroid withdrawal in type 1 autoimmune hepatitis. Liver Int 2003;23(2):116–123PubMedCrossRef

79.

Dhaliwal HK, Hoeroldt BS, Dube AK, McFarlane E, Underwood JC, Karajeh MA, et al. Long-term prognostic significance of persisting histological activity despite biochemical remission in autoimmune hepatitis. Am J Gastroenterol 2015;110(7):993–999PubMedCrossRef

80.

FF van den Brand, KS van der Veen, YS de Boer, NM van Gerven, BI Lissenberg-Witte, U Beuers et al. Increased mortality among patients with vs without cirrhosis and autoimmune hepatitis. Clin Gastroenterol Hepatol. 2019;17(5):940–947.e2. https://doi.org/10.1016/j.cgh.2018.09.046.

81.

Puustinen L, Boyd S, Mustonen H, Arkkila P, Arola J, Farkkila M. Prognostic value of clinical variables and liver histology for development of fibrosis and cirrhosis in autoimmune hepatitis. Scand J Gastroenterol 2017;52(3):321–327PubMedCrossRef

82.

Harada K, Hiep NC, Ohira H. Challenges and difficulties in pathological diagnosis of autoimmune hepatitis. Hepatol Res 2017;47(10):963–971. https://doi.org/10.1111/hepr.12931PubMedCrossRef

83.

Stirnimann G, Ebadi M, Czaja AJ, Montano-Loza AJ. Recurrent and de novo autoimmune hepatitis. Liver Transpl 2019;25(1):152–166PubMedCrossRef

84.

Chapin CA, Mohammad S, Bass LM, Taylor SA, Kelly S, Alonso EM. Liver biopsy can be safely performed in pediatric acute liver failure to aid in diagnosis and management. J Pediatr Gastroenterol Nutr 2018;67(4):441–445.PubMedCrossRef

85.

Stift J, Semmler G, Walzel C, Mandorfer M, Schwarzer R, Schwabl P, et al. Transjugular aspiration liver biopsy performed by hepatologists trained in HVPG measurements is safe and provides important diagnostic information. Dig Liver Dis 2019;51(8):1144–1151. https://doi.org/10.1016/j.dld.2019.01.020PubMedCrossRef

86.

Cholongitas E, Burroughs AK. Liver: transjugular liver biopsy yields high-quality samples. Nat Rev Gastroenterol Hepatol 2012;9(9):491–492PubMedCrossRef

87.

Kalambokis G, Manousou P, Vibhakorn S, Marelli L, Cholongitas E, Senzolo M, et al. Transjugular liver biopsy–indications, adequacy, quality of specimens, and complications–a systematic review. J Hepatol 2007;47(2):284–294PubMedCrossRef

88.

van Leeuwen DJ, Alves V, Balabaud C, Bhathal PS, Bioulac-Sage P, Colombari R, et al. Acute-on-chronic liver failure 2018: a need for (urgent) liver biopsy? Expert Rev Gastroenterol Hepatol 2018;12(6):565–573PubMedCrossRef

89.

Denzer U, Arnoldy A, Kanzler S, Galle PR, Dienes HP, Lohse AW. Prospective randomized comparison of minilaparoscopy and percutaneous liver biopsy: diagnosis of cirrhosis and complications. J Clin Gastroenterol 2007;41(1):103–110PubMedCrossRef

90.

Denzer U, Helmreich-Becker I, Galle PR, Lohse AW. Liver assessment and biopsy in patients with marked coagulopathy: value of mini-laparoscopy and control of bleeding. Am J Gastroenterol 2003;98(4):893–900PubMedCrossRef

91.

Helmreich-Becker I, zum Buschenfelde KHM, Lohse AW. Safety and feasibility of a new minimally invasive diagnostic laparoscopy technique. Endoscopy 1998;30(9):756–762PubMedCrossRef

92.

Zeng J, Huang Z-P, Zheng J, Wu T, Zheng R-Q. Non-invasive assessment of liver fibrosis using two-dimensional shear wave elastography in patients with autoimmune liver diseases. World J Gastroenterol 2017;23(26):4839–4846PubMedPubMedCentralCrossRef

93.

Hartl J, Ehlken H, Sebode M, Peiseler M, Krech T, Zenouzi R, et al. Usefulness of biochemical remission and transient elastography in monitoring disease course in autoimmune hepatitis. J Hepatol 2018;68(4):754–763. https://doi.org/10.1016/j.jhep.2017.11.020PubMedCrossRef

94.

J Hartl, H Ehlken, M Sebode, M Peiseler, T Krech, R Zenouzi et al. (2017) Usefulness of biochemical remission and transient elastography in monitoring disease course in autoimmune hepatitis. J Hepatol. 2018:68(4):754–763. https://doi.org/10.1016/j.jhep.2017.11.020.

95.

Yada N, Sakurai T, Minami T, Arizumi T, Takita M, Hagiwara S, et al. Influence of liver inflammation on liver stiffness measurement in patients with autoimmune hepatitis evaluation by combinational elastography. Oncology 2017;92(Suppl 1):10–15PubMedCrossRef

96.

Guo L, Zheng L, Hu L, Zhou H, Yu L, Liang W. Transient elastography (Fibroscan) performs better than non-invasive markers in assessing liver fibrosis and cirrhosis in autoimmune hepatitis patients. Med Sci Monit 2017;23:5106–5112PubMedPubMedCentralCrossRef

97.

Xu Q, Sheng L, Bao H, Chen X, Guo C, Li H, et al. Evaluation of transient elastography in assessing liver fibrosis in patients with autoimmune hepatitis. J Gastroenterol Hepatol 2017;32(3):639–644PubMedCrossRef

98.

Hartl J, Denzer U, Ehlken H, Zenouzi R, Peiseler M, Sebode M, et al. Transient elastography in autoimmune hepatitis: timing determines the impact of inflammation and fibrosis. J Hepatol 2016;65(4):769–775PubMedCrossRef

99.

Czaja AJ, Carpenter HA. Sensitivity, specificity, and predictability of biopsy interpretations in chronic hepatitis. Gastroenterology 1993;105(6):1824–1832PubMedCrossRef

100.

Mieli-Vergani G, Vergani D, Baumann U, Czubkowski P, Debray D, Dezsofi A, et al. Diagnosis and management of pediatric autoimmune liver disease: ESPGHAN hepatology committee position statement. J Pediatr Gastroenterol Nutr 2018;66(2):345–360PubMedCrossRef

101.

Canh HN, Harada K, Ouchi H, Sato Y, Tsuneyama K, Kage M, et al. Acute presentation of autoimmune hepatitis: a multicentre study with detailed histological evaluation in a large cohort of patients. J Clin Pathol 2017;70(11):961–969. https://doi.org/10.1136/jclinpath-2016-204271.CrossRef

102.

Fujiwara K, Fukuda Y, Yokosuka O. Precise histological evaluation of liver biopsy specimen is indispensable for diagnosis and treatment of acute-onset autoimmune hepatitis. J Gastroenterol 2008;43(12):951–958PubMedCrossRef

103.

Fujiwara K, Nakano M, Yasui S, Okitsu K, Yonemitsu Y, Yokosuka O. Advanced histology and impaired liver regeneration are associated with disease severity in acute-onset autoimmune hepatitis. Histopathology 2011;58(5):693–704PubMedCrossRef

104.

Burgart LJ, Batts KP, Ludwig J, Nikias GA, Czaja AJ. Recent-onset autoimmune hepatitis. Biopsy findings and clinical correlations. Am J Surg Pathol 1995;19(6):699–708PubMedCrossRef

105.

Takahashi A, Arinaga-Hino T, Ohira H, Torimura T, Zeniya M, Abe M et al. Autoimmune hepatitis in Japan: trends in a nationwide survey. J Gastroenterol. 2017;52(5):631–640. https://doi.org/10.1007/s00535-016-1267-0

106.

Desmet VJ, Gerber M, Hoofnagle JH, Manns M, Scheuer PJ. Classification of chronic hepatitis: diagnosis, grading and staging. Hepatology 1994;19(6):1513–1520PubMedCrossRef

107.

de Boer YS, van Nieuwkerk CMJ, Witte BI, Mulder CJJ, Bouma G, Bloemena E. Assessment of the histopathological key features in autoimmune hepatitis. Histopathology 2015;66(3):351–362PubMedCrossRef

108.

K Washington, MP Manns (2018), Autoimmune Hepatitis. Macsween's Pathology of the Liver. AD Burt, LD Ferrell, SG Hübscher (Ed) 7th ed: Elsevier 491-514

109.

Gonzalez RS, Washington K. Primary biliary cholangitis and autoimmune hepatitis. Surg Pathol Clin 2018;11(2):329–349PubMedCrossRef

110.

Lefkowitch JH, Schiff ER, Davis GL, Perrillo RP, Lindsay K, Bodenheimer HC Jr, et al. Pathological diagnosis of chronic hepatitis C: a multicenter comparative study with chronic hepatitis B. The hepatitis interventional therapy group. Gastroenterology 1993;104(2):595–603PubMedCrossRef

111.

Bach N, Thung SN, Schaffner F. The histological features of chronic hepatitis C and autoimmune chronic hepatitis: a comparative analysis. Hepatology 1992;15(4):572–577PubMedCrossRef

112.

Suzuki A, Brunt EM, Kleiner DE, Miquel R, Smyrk TC, Andrade RJ, et al. The use of liver biopsy evaluation in discrimination of idiopathic autoimmune hepatitis versus drug-induced liver injury. Hepatology 2011;54(3):931–939PubMedCrossRef

113.

Hisamochi A, Kage M, Ide T, Arinaga-Hino T, Amano K, Kuwahara R, et al. An analysis of drug-induced liver injury, which showed histological findings similar to autoimmune hepatitis. J Gastroenterol 2016;51(6):597–607PubMedCrossRef

114.

De Martin E, Michot J-M, Papouin B, Champiat S, Mateus C, Lambotte O, et al. Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors. J Hepatol 2018;68(6):1181–1190PubMedCrossRef

115.

Kleiner DE, Chalasani NP, Lee WM, Fontana RJ, Bonkovsky HL, Watkins PB, et al. Hepatic histological findings in suspected drug-induced liver injury: systematic evaluation and clinical associations. Hepatology 2014;59(2):661–670PubMedCrossRef

116.

Foureau DM, Walling TL, Maddukuri V, Anderson W, Culbreath K, Kleiner DE, et al. Comparative analysis of portal hepatic infiltrating leucocytes in acute drug-induced liver injury, idiopathic autoimmune and viral hepatitis. Clin Exp Immunol 2015;180(1):40–51PubMedPubMedCentralCrossRef

117.

Mietkiewski JM, Scheuer PJ. Immunoglobulin-containing plasma cells in acute hepatitis. Liver 1985;5(2):84–88PubMedCrossRef

118.

de Boer YS, Kosinski AS, Urban TJ, Zhao Z, Long N, Chalasani N, et al. Features of autoimmune hepatitis in patients with drug-induced liver injury. Clin Gastroenterol Hepatol 2017;15(1):103-112.e2PubMedCrossRef

119.

Balitzer D, Shafizadeh N, Peters MG, Ferrell LD, Alshak N, Kakar S. Autoimmune hepatitis: review of histologic features included in the simplified criteria proposed by the international autoimmune hepatitis group and proposal for new histologic criteria. Mod Pathol 2017;30(5):773–783. https://doi.org/10.1038/modpathol.2016.267.PubMedCrossRef

120.

Tiniakos DG, Brain JG, Bury YA. Role of histopathology in autoimmune hepatitis. Dig Dis 2015;33(Suppl. 2):53–64PubMedCrossRef

121.

Miao Q, Bian Z, Tang R, Zhang H, Wang Q, Huang S, et al. Emperipolesis mediated by CD8 T cells is a characteristic histopathologic feature of autoimmune hepatitis. Clin Rev Allergy Immunol 2015;48(2–3):226–235PubMedCrossRef

122.

Himoto T, Kadota K, Fujita K, Nomura T, Morishita A, Yoneyama H, et al. The pathological appearance of hyaline droplets in Kupffer cells is not specific to patients with autoimmune hepatitis. Int J Clin Exp Pathol 2017;10(8):8703–8708PubMedPubMedCentral

123.

Lotowska JM, Sobaniec-Lotowska ME, Daniluk U, Lebensztejn DM. Glassy droplet inclusions within the cytoplasm of Kupffer cells: a novel ultrastructural feature for the diagnosis of pediatric autoimmune hepatitis. Dig Liver Dis 2017;49(8):929–933PubMedCrossRef

124.

Gurung A, Assis DN, McCarty TR, Mitchell KA, Boyer JL, Jain D. Histologic features of autoimmune hepatitis: a critical appraisal. Hum Pathol 2018;82:51–60PubMedCrossRef

125.

Aizawa Y, Abe H, Sugita T, Seki N, Chuganji Y, Furumoto Y, et al. Centrilobular zonal necrosis as a hallmark of a distinctive subtype of autoimmune hepatitis. Eur J Gastroenterol Hepatol 2016;28(4):391–397PubMedPubMedCentralCrossRef

126.

Kessler WR, Cummings OW, Eckert G, Chalasani N, Lumeng L, Kwo PY. Fulminant hepatic failure as the initial presentation of acute autoimmune hepatitis. Clin Gastroenterol Hepatol 2004;2(7):625–631PubMedCrossRef

127.

Abe K, Kanno Y, Okai K, Katsushima F, Monoe K, Saito H, et al. Centrilobular necrosis in acute presentation of Japanese patients with type 1 autoimmune hepatitis. World J Hepatol 2012;4(9):262–267PubMedPubMedCentralCrossRef

128.

Fujiwara K, Yasui S, Tawada A, Fukuda Y, Nakano M, Yokosuka O. Diagnostic value and utility of the simplified international autoimmune hepatitis group criteria in acute-onset autoimmune hepatitis. Liver Int 2011;31(7):1013–1020PubMedCrossRef

129.

Hofer H, Oesterreicher C, Wrba F, Ferenci P, Penner E. Centrilobular necrosis in autoimmune hepatitis: a histological feature associated with acute clinical presentation. J Clin Pathol 2006;59(3):246–249PubMedPubMedCentralCrossRef

130.

Miyake Y, Iwasaki Y, Terada R, Onishi T, Okamoto R, Takaguchi K, et al. Clinical features of Japanese type 1 autoimmune hepatitis patients with zone III necrosis. Hepatol Res 2007;37(10):801–805PubMedCrossRef

131.

132.

Te HS, Koukoulis G, Ganger DR. Autoimmune hepatitis: a histological variant associated with prominent centrilobular necrosis. Gut 1997;41(2):269–271PubMedCrossRef

133.

Pratt DS, Fawaz KA, Rabson A, Dellelis R, Kaplan MM. A novel histological lesion in glucocorticoid-responsive chronic hepatitis. Gastroenterology 1997;113(2):664–668PubMedCrossRef

134.

Ranvir S, Nair S, Farr G, Mason A, Perrillo R. Acute autoimmune hepatitis presenting with centrizonal liver disease: case report and review of the literature. Am J Gastroenterol 2002;97(10):2679–2683

135.

Misdraji J, Thiim M, Graeme-Cook FM. Autoimmune hepatitis with centrilobular necrosis. Am J Surg Pathol 2004;28(4):471–478PubMedCrossRef

136.

Zen Y, Notsumata K, Tanaka N, Nakanuma Y. Hepatic centrilobular zonal necrosis with positive antinuclear antibody: a unique subtype or early disease of autoimmune hepatitis? Hum Pathol 2007;38(11):1669–1675PubMedCrossRef

137.

Abe M, Onji M, Kawai-Ninomiya K, Michitaka K, Matsuura B, Hiasa Y, et al. Clinicopathologic features of the severe form of acute type 1 autoimmune hepatitis. Clin Gastroenterol Hepatol 2007;5(2):255–258PubMedCrossRef

138.

Yoshizawa K, Joshita S, Matsumoto A, Umemura T, Tanaka E, Morita S, et al. Incidence and prevalence of autoimmune hepatitis in the Ueda area, Japan. Hepatol Res 2016;46(9):878–883PubMedCrossRef

139.

Fujiwara K, Fukuda Y, Seza K, Saito M, Yasui S, Nakano M, et al. High level of persistent liver injury is one of clinical characteristics in treatment-naïve acute onset autoimmune hepatitis: experience in a community hospital. J Hepatobiliary Pancreat Sci 2016;23(3):174–180PubMedCrossRef

140.

Fujiwara K, Yasui S, Yokosuka O. Autoimmune acute liver failure: an emerging etiology for intractable acute liver failure. Hepatol Int 2013;7(2):335–346PubMedCrossRef

141.

Okano N, Yamamoto K, Sakaguchi K, Miyake Y, Shimada N, Hakoda T, et al. Clinicopathological features of acute-onset autoimmune hepatitis. Hepatol Res 2003;25(3):263–270PubMedCrossRef

142.

Fujiwara K, Yasui S, Tawada A, Okitsu K, Yonemitsu Y, Chiba T, et al. Autoimmune fulminant liver failure in adults: experience in a Japanese center. Hepatol Res 2011;41(2):133–141PubMedCrossRef

143.

Fujiwara K, Yasui S, Yonemitsu Y, Arai M, Kanda T, Fukuda Y, et al. Analysis of infectious complications and timing for emergency liver transplantation in autoimmune acute liver failure. J Hepatobiliary Pancreat Sci 2016;23(4):212–219PubMedCrossRef

144.

Nikias GA, Batts KP, Czaja AJ. The nature and prognostic implications of autoimmune hepatitis with an acute presentation. J Hepatol 1994;21(5):866–871PubMedCrossRef

145.

Yasui S, Fujiwara K, Yonemitsu Y, Oda S, Nakano M, Yokosuka O. Clinicopathological features of severe and fulminant forms of autoimmune hepatitis. J Gastroenterol 2011;46(3):378–390PubMedCrossRef

146.

Ferrari R, Pappas G, Agostinelli D, Muratori P, Muratori L, Lenzi M, et al. Type 1 autoimmune hepatitis: patterns of clinical presentation and differential diagnosis of the ‘acute’ type. QJM 2004;97(7):407–412PubMedCrossRef

147.

van Gerven NM, Verwer BJ, Witte BI, van Erpecum KJ, van Buuren HR, Maijers I, et al. Epidemiology and clinical characteristics of autoimmune hepatitis in the Netherlands. Scand J Gastroenterol 2014;49(10):1245–1254PubMedCrossRef

148.

Than NN, Ching DK, Hodson J, McDowell P, Mann J, Gupta R, et al. Difference in clinical presentation, immunology profile and treatment response of type 1 autoimmune hepatitis between United Kingdom and Singapore patients. Hepatol Int 2016;10(4):673–679PubMedCrossRef

149.

Takahashi A, Arinaga-Hino T, Ohira H, Torimura T, Zeniya M, Abe M, et al. Autoimmune hepatitis in Japan: trends in a nationwide survey. J Gastroenterol 2017;52(5):631–640PubMedCrossRef

150.

Burt AD, Lackner C, Tiniakos DG. Diagnosis and assessment of NAFLD: definitions and histopathological classification. Semin Liver Dis 2015;35(3):207–220PubMedCrossRef

151.

Wang Z, Sheng L, Yang Y, Yang F, Xiao X, Hua J, et al. The Management of autoimmune hepatitis patients with decompensated cirrhosis: real-world experience and a comprehensive review. Clin Rev Allergy Immunol 2017;52(3):424–435PubMedCrossRef

152.

Wang QX, Jiang WJ, Miao Q, Xiao X, Zhang HY, Huang SS, et al. Clinical and histological features of autoantibody-negative autoimmune hepatitis in Chinese patients: a single center experience. J Dig Dis 2013;14(4):175–180PubMedCrossRef

153.

Baeres M, Herkel J, Czaja AJ, Wies I, Kanzler S, Cancado EL, et al. Establishment of standardised SLA/LP immunoassays: specificity for autoimmune hepatitis, worldwide occurrence, and clinical characteristics. Gut 2002;51(2):259–264PubMedPubMedCentralCrossRef

154.

Efe C, Ozaslan E, Wahlin S, Purnak T, Muratori L, Quarneti C, et al. Antibodies to soluble liver antigen in patients with various liver diseases: a multicentre study. Liver Int 2013;33(2):190–196PubMedCrossRef

155.

Umemura T, Joshita S, Saito H, Yoshizawa K, Norman GL, Tanaka E, et al. KIR/HLA genotypes confer susceptibility and progression in patients with autoimmune hepatitis. JHEP Rep 2019;1(5):353–360PubMedPubMedCentralCrossRef

156.

Yilmaz B, Unlu O, Evcen R, Ugurluoglu C. Acute onset seronegative autoimmune hepatitis: are simplified diagnostic criteria sufficient? Eur J Gastroenterol Hepatol 2016;28(5):607–608PubMedCrossRef

157.

Czaja AJ. Behavior and significance of autoantibodies in type 1 autoimmune hepatitis. J Hepatol 1999;30(3):394–401PubMedCrossRef

158.

Poynard T, Ngo Y, Perazzo H, Munteanu M, Lebray P, Moussalli J, et al. Prognostic value of liver fibrosis biomarkers: a meta-analysis. Gastroenterol Hepatol (N Y) 2011;7(7):445–454

159.

Wai CT, Greenson JK, Fontana RJ, Kalbfleisch JD, Marrero JA, Conjeevaram HS, et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 2003;38(2):518–526PubMedCrossRef

160.

Shah AG, Lydecker A, Murray K, Tetri BN, Contos MJ, Sanyal AJ. Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2009;7(10):1104–1112PubMedPubMedCentralCrossRef

161.

MS Gungoren, C Efe, T Kav, F Akbiyik (2018) Diagnostic accuracy of enhanced liver fibrosis (ELF) test for significant fibrosis in patients with autoimmune hepatitis. J Lab Precis Med 3(3)

162.

Efe C, Cengiz M, Kahramanoğlu-Aksoy E, Yilmaz B, Özşeker B, Beyazt Y, et al. Angiotensin-converting enzyme for noninvasive assessment of liver fibrosis in autoimmune hepatitis. Eur J Gastroenterol Hepatol 2015;27(6):649–654. https://doi.org/10.1097/MEG.0000000000000355PubMedCrossRef

163.

Liu L, Cao J, Zhong Z, Guo Z, Jiang Y, Bai Y, et al. Noninvasive indicators predict advanced liver fibrosis in autoimmune hepatitis patients. J Clin Lab Anal 2019;33(7):e22922PubMedPubMedCentralCrossRef

164.

Yuan X, Duan SZ, Cao J, Gao N, Xu J, Zhang L. Noninvasive inflammatory markers for assessing liver fibrosis stage in autoimmune hepatitis patients. Eur J Gastroenterol Hepatol 2019;31(11):1467–1474PubMedPubMedCentralCrossRef

165.

Zeng T, Yu J, Tan L, Wu Y, Tian Y, Wu Q, et al. Noninvasive indices for monitoring disease course in Chinese patients with autoimmune hepatitis. Clin Chim Acta 2018;486:135–141PubMedCrossRef

166.

Wang QX, Shen L, Qiu DK, Bao H, Chen XY, Zeng MD, et al. Validation of transient elastography (Fibroscan) in assessment of hepatic fibrosis in autoimmune hepatitis. Zhonghua Gan Zang Bing Za Zhi 2011;19(10):782–784PubMed

167.

Obara N, Ueno Y, Fukushima K, Nakagome Y, Kakazu E, Kimura O, et al. Transient elastography for measurement of liver stiffness measurement can detect early significant hepatic fibrosis in Japanese patients with viral and nonviral liver diseases. J Gastroenterol 2008;43(9):720–728PubMedCrossRef

168.

Efe C, Gungoren MS, Ozaslan E, Akbiyik F, Kav T. Acoustic radiation force impulse (ARFI) for fibrosis staging in patients with autoimmune hepatitis. Hepatogastroenterology 2015;62(139):670–672PubMed

169.

Goertz RS, GaBmann L, Strobel D, Wildner D, Schellhaas B, Neurath MF, et al. Acoustic radiation force impulse (ARFI) elastography in autoimmune and cholestatic liver diseases. Ann Hepatol 2019;18(1):23–29PubMedCrossRef

170.

Wang J, Malik N, Yin M, Smyrk TC, Czaja AJ, Ehman RL, et al. Magnetic resonance elastography is accurate in detecting advanced fibrosis in autoimmune hepatitis. World J Gastroenterol 2017;23(5):859–868PubMedPubMedCentralCrossRef

171.

Czaja AJ. Performance parameters of the diagnostic scoring systems for autoimmune hepatitis. Hepatology 2008;48(5):1540–1548PubMedCrossRef

172.

Johnson PJ, McFarlane IG. Meeting report: international autoimmune hepatitis group. Hepatology 1993;18(4):998–1005PubMedCrossRef

173.

Miyake Y, Iwasaki Y, Kobashi H, Yasunaka T, Ikeda F, Takaki A, et al. Clinical features of autoimmune hepatitis diagnosed based on simplified criteria of the international autoimmune hepatitis group. Dig Liver Dis 2010;42(3):210–215PubMedCrossRef

174.

Hennes EM, Zeniya M, Czaja AJ, Pares A, Dalekos GN, Krawitt EL, et al. Simplified criteria for the diagnosis of autoimmune hepatitis. Hepatology 2008;48(1):169–176PubMedCrossRef

175.

Yeoman AD, Westbrook RH, Al-Chalabi T, Carey I, Heaton ND, Portmann BC, et al. Diagnostic value and utility of the simplified international autoimmune hepatitis group (IAIHG) criteria in acute and chronic liver disease. Hepatology 2009;50(2):538–545PubMedCrossRef

176.

Qiu D, Wang Q, Wang H, Xie Q, Zang G, Jiang H, et al. Validation of the simplified criteria for diagnosis of autoimmune hepatitis in Chinese patients. J Hepatol 2011;54(2):340–347PubMedCrossRef

177.

Kim BH, Kim YJ, Jeong SH, Tak WY, Ahn SH, Lee YJ, et al. Clinical features of autoimmune hepatitis and comparison of two diagnostic criteria in Korea: a nationwide, multicenter study. J Gastroenterol Hepatol 2013;28(1):128–134PubMedCrossRef

178.

Chazouilleres O, Wendum D, Serfaty L, Montembault S, Rosmorduc O, Poupon R. Primary biliary cirrhosis-autoimmune hepatitis overlap syndrome: clinical features and response to therapy. Hepatology 1998;28(2):296–301PubMedCrossRef

179.

Wang Q, Selmi C, Zhou X, Qiu D, Li Z, Miao Q, et al. Epigenetic considerations and the clinical reevaluation of the overlap syndrome between primary biliary cirrhosis and autoimmune hepatitis. J Autoimmun 2013;41:140–145PubMedCrossRef

180.

Chapman R, Fevery J, Kalloo A, Nagorney DM, Boberg KM, Shneider B, et al. Diagnosis and management of primary sclerosing cholangitis. Hepatology 2010;51(2):660–678PubMedCrossRef

181.

Kaya M, Angulo P, Lindor KD. Overlap of autoimmune hepatitis and primary sclerosing cholangitis: an evaluation of a modified scoring system. J Hepatol 2000;33(4):537–542PubMedCrossRef

182.

Lian M, Li B, Xiao X, Yang Y, Jiang P, Yan L, et al. Comparative clinical characteristics and natural history of three variants of sclerosing cholangitis: IgG4-related SC, PSC/AIH and PSC alone. Autoimmun Rev 2017;16(8):875–882PubMedCrossRef

183.

deLemos AS, Foureau DM, Jacobs C, Ahrens W, Russo MW, Bonkovsky HL. Drug-induced liver injury with autoimmune features. Semin Liver Dis 2014;34(2):194–204PubMedCrossRef

184.

Tsuneyama K, Baba H, Kikuchi K, Nishida T, Nomoto K, Hayashi S, et al. Autoimmune features in metabolic liver disease: a single-center experience and review of the literature. Clin Rev Allergy Immunol 2013;45(1):143–148PubMedCrossRef

185.

Takahashi A, Arinaga-Hino T, Ohira H, Abe K, Torimura T, Zeniya M, et al. Non-alcoholic fatty liver disease in patients with autoimmune hepatitis. JGH Open 2018;2(2):54–58PubMedPubMedCentralCrossRef

186.

Taubert R, Diestelhorst J, Junge N, Kirstein MM, Pischke S, Vogel A, et al. Increased seroprevalence of HAV and parvovirus B19 in children and of HEV in adults at diagnosis of autoimmune hepatitis. Sci Rep 2018;8(1):17452PubMedPubMedCentralCrossRef

187.

Pischke S, Gisa A, Suneetha PV, Wiegand SB, Taubert R, Schlue J, et al. Increased HEV seroprevalence in patients with autoimmune hepatitis. PLoS ONE 2014;9(1):e85330PubMedPubMedCentralCrossRef

188.

Sener AG, Aydin N, Ceylan C, Kirdar S. Investigation of antinuclear antibodies in chronic hepatitis B patients. Mikrobiyol Bul 2018;52(4):425–430PubMedCrossRef

189.

Gilman AJ, Le AK, Zhao C, Hoang J, Yasukawa LA, Weber SC, et al. Autoantibodies in chronic hepatitis C virus infection: impact on clinical outcomes and extrahepatic manifestations. BMJ Open Gastroenterol 2018;5(1):e000203PubMedPubMedCentralCrossRef

190.

Sui M, Wu R, Hu X, Zhang H, Jiang J, Yang Y, et al. Low prevalence of hepatitis B virus infection in patients with autoimmune diseases in a Chinese patient population. J Viral Hepat 2014;21(12):925–929PubMedCrossRef

191.

Shantha S, Thyagarajan SP, Premavathy RK, Sukumar RG, Mohan KV, Palanisamy KR, et al. Correlation of autoimmune reactivity with hepatitis B and C virus (HBV and HCV) infection in histologically proven chronic liver diseases. Indian J Med Microbiol 2002;20(1):12–15PubMed

192.

Efe C, Wahlin S, Ozaslan E, Purnak T, Muratori L, Quarneti C, et al. Diagnostic difficulties, therapeutic strategies, and performance of scoring systems in patients with autoimmune hepatitis and concurrent hepatitis B/C. Scand J Gastroenterol 2013;48(4):504–508PubMedCrossRef

193.

Yener S, Akarsu M, Karacanci C, Sengul B, Topalak O, Biberoglu K, et al. Wilson’s disease with coexisting autoimmune hepatitis. J Gastroenterol Hepatol 2004;19(1):114–116PubMedCrossRef

194.

Acharya GK, Liao HI, Frunza-Stefan S, Patel R, Khaing M. Autoimmune hepatitis: diagnostic dilemma when it is disguised as iron overload syndrome. J Clin Exp Hepatol 2017;7(3):269–273PubMedPubMedCentralCrossRef

195.

Hohler T, Leininger S, Kohler HH, Schirmacher P, Galle PR. Heterozygosity for the hemochromatosis gene in liver diseases–prevalence and effects on liver histology. Liver 2000;20(6):482–486PubMedCrossRef

196.

Efe C, Ozaslan E, Heurgue-Berlot A, Kav T, Masi C, Purnak T, et al. Sequential presentation of primary biliary cirrhosis and autoimmune hepatitis. Eur J Gastroenterol Hepatol 2014;26(5):532–537PubMedCrossRef

197.

Boberg KM, Fausa O, Haaland T, Holter E, Mellbye OJ, Spurkland A, et al. Features of autoimmune hepatitis in primary sclerosing cholangitis: an evaluation of 114 primary sclerosing cholangitis patients according to a scoring system for the diagnosis of autoimmune hepatitis. Hepatology 1996;23(6):1369–1376PubMedCrossRef

198.

Cook GC, Mulligan R, Sherlock S. Controlled prospective trial of corticosteroid therapy in active chronic hepatitis. Q J Med 1971;40(158):159–185PubMedCrossRef

199.

Murray-Lyon I, Stern R, Williams R. Controlled trial of prednisone and azathioprine in active chronic hepatitis. Lancet 1973;1(7806):735–737PubMedCrossRef

200.

Soloway R, Summerskill W, Baggenstoss A, Geall M, Gitnick G, Elveback I, et al. Clinical, biochemical, and histological remission of severe chronic active liver disease: a controlled study of treatments and early prognosis. Gastroenterology 1972;63(5):820–833PubMedCrossRef

201.

Summerskill W, Korman M, Ammon H, Baggenstoss A. Prednisone for chronic active liver disease: dose titration, standard dose, and combination with azathioprine compared. Gut 1975;16(11):876–883PubMedPubMedCentralCrossRef

202.

Tage-Jensen U, Schlichting P, Aldershvile J, Andersen P, Dietrichson O, Hardt F, et al. Azathioprine versus prednisone in non-alcoholic chronic liver disease (CLD). Relation to a serological classification. Liver 1982;2(2):95–103PubMedCrossRef

203.

Lamers MM, van Oijen MG, Pronk M, Drenth JP. Treatment options for autoimmune hepatitis: a systematic review of randomized controlled trials. J Hepatol 2010;53(1):191–198PubMedCrossRef

204.

Baggenstoss AH, Soloway RD, Summerskill WH, Elveback LR, Schoenfield LJ. Chronic active liver disease. The range of histologic lesions, their response to treatment, and evolution. Hum Pathol 1972;3(2):183–198PubMedCrossRef

205.

Cooksley WG, Bradbear RA, Robinson W, Harrison M, Halliday JW, Powell LW, et al. The prognosis of chronic active hepatitis without cirrhosis in relation to bridging necrosis. Hepatology 1986;6(3):345–348PubMedCrossRef

206.

Yoshizawa K, Matsumoto A, Ichijo T, Umemura T, Joshita S, Komatsu M, et al. Long-term outcome of Japanese patients with type 1 autoimmune hepatitis. Hepatology 2012;56(2):668–676PubMedCrossRef

207.

Amarapurkar D, Dharod M, Amarapurkar A. Autoimmune hepatitis in India: single tertiary referral centre experience. Trop Gastroenterol 2015;36(1):36–45PubMedCrossRef

208.

Muratori L, Muratori P, Lanzoni G, Ferri S, Lenzi M. Application of the 2010 American association for the study of liver diseases criteria of remission to a cohort of Italian patients with autoimmune hepatitis. Hepatology 2010;52(5):1857–1857PubMedCrossRef

209.

Luth S, Herkel J, Kanzler S, Frenzel C, Galle PR, Dienes HP, et al. Serologic markers compared with liver biopsy for monitoring disease activity in autoimmune hepatitis. J Clin Gastroenterol 2008;42(8):926–930PubMedCrossRef

210.

Pape S, Gevers TJG, Vrolijk JM, van Hoek B, Bouma G, van Nieuwkerk CMJ, et al. Rapid response to treatment of autoimmune hepatitis associated with remission at 6 and 12 months. Clin Gastroenterol Hepatol 2020;18(7):1609-1617.e4PubMedCrossRef

211.

Dyson JK, De Martin E, Dalekos GN, Drenth JPH, Herkel J, Hubscher SG, et al. Review article: unanswered clinical and research questions in autoimmune hepatitis-conclusions of the international autoimmune hepatitis group research workshop. Aliment Pharmacol Ther 2019;49(5):528–536PubMedCrossRef

212.

Schramm C, Wahl I, Weiler-Normann C, Voigt K, Wiegard C, Glaubke C, et al. Health-related quality of life, depression, and anxiety in patients with autoimmune hepatitis. J Hepatol 2014;60(3):618–624PubMedCrossRef

213.

Sockalingam S, Blank D, Abdelhamid N, Abbey SE, Hirschfield GM. Identifying opportunities to improve management of autoimmune hepatitis: evaluation of drug adherence and psychosocial factors. J Hepatol 2012;57(6):1299–1304PubMedCrossRef

214.

Czaja AJ. Features and consequences of untreated type 1 autoimmune hepatitis. Liver Int 2009;29(6):816–823PubMedCrossRef

215.

Czaja AJ, Carpenter HA. Decreased fibrosis during corticosteroid therapy of autoimmune hepatitis. J Hepatol 2004;40(4):646–652PubMedCrossRef

216.

Czaja AJ. Hepatic inflammation and progressive liver fibrosis in chronic liver disease. World J Gastroenterol 2014;20(10):2515–2532PubMedPubMedCentralCrossRef

217.

Czaja AJ. Review article: the prevention and reversal of hepatic fibrosis in autoimmune hepatitis. Aliment Pharmacol Ther 2014;39(4):385–406PubMedCrossRef

218.

Beretta-Piccoli BT, Mieli-Vergani G, Vergani D. Autoimmune hepatitis: Standard treatment and systematic review of alternative treatments. World J Gastroenterol 2017;23(33):6030–6048CrossRef

219.

Orlando R, Lirussi F, Okolicsanyi L. Laparoscopy and liver biopsy: further evidence that the two procedures improve the diagnosis of liver cirrhosis. A retrospective study of 1003 consecutive examinations. J Clin Gastroenterol 1990;12(1):47–52PubMed

220.

Kirk AP, Jain S, Pocock S, Thomas HC, Sherlock S. Late results of the royal free hospital prospective controlled trial of prednisolone therapy in hepatitis B surface antigen negative chronic active hepatitis. Gut 1980;21(1):78–83PubMedPubMedCentralCrossRef

221.

Yeoman AD, Westbrook RH, Zen Y, Bernal W, Al-Chalabi T, Wendon JA, et al. Prognosis of acute severe autoimmune hepatitis (AS-AIH): the role of corticosteroids in modifying outcome. J Hepatol 2014;61(4):876–882PubMedCrossRef

222.

Czaja AJ. Rapidity of treatment response and outcome in type 1 autoimmune hepatitis. J Hepatol 2009;51(1):161–167PubMedCrossRef

223.

Purnak T, Efe C, Kav T, Wahlin S, Ozaslan E. Treatment response and outcome with two different prednisolone regimens in autoimmune hepatitis. Dig Dis Sci 2017;62(10):2900–2907PubMedCrossRef

224.

Zhang C, Wu SS, Dong XQ, Wu Z, Zhao H, Wang GQ. The efficacy and safety of different doses of glucocorticoid for autoimmune hepatitis: a systematic review and meta-analysis. Medicine (Baltimore) 2019;98(52):e18313CrossRef

225.

Pape S, Gevers TJG, Belias M, Mustafajev IF, Vrolijk JM, van Hoek B, et al. Predniso(lo)ne dosage and chance of remission in patients with autoimmune hepatitis. Clin Gastroenterol Hepatol 2019;17(10):2068-2075.e2PubMedCrossRef

226.

Pape S, Gevers TJG, Vrolijk JM, van Hoek B, Bouma G, van Nieuwkerk CMJ, et al. High discontinuation rate of azathioprine in autoimmune hepatitis, independent of time of treatment initiation. Liver Int 2020;40(9):2164–2171PubMedPubMedCentralCrossRef

227.

Newman WG, Payne K, Tricker K, Roberts SA, Fargher E, Pushpakom S, et al. A pragmatic randomized controlled trial of thiopurine methyltransferase genotyping prior to azathioprine treatment: the TARGET study. Pharmacogenomics 2011;12(6):815–826PubMedCrossRef

228.

American Gastroenterological Association. American Gastroenterological Association medical position statement: osteoporosis in hepatic disorders. Gastroenterology 2003;125(3):937–940CrossRef

229.

Wong LL, Fisher HF, Stocken DD, Rice S, Khanna A, Heneghan MA, et al. The impact of autoimmune hepatitis and its treatment on health utility. Hepatology 2018;68(4):1487–1497PubMedCrossRef

230.

van den Brand FF, van der Veen KS, Lissenberg-Witte BI, de Boer YS, van Hoek B, Drenth JPH, et al. Adverse events related to low dose corticosteroids in autoimmune hepatitis. Aliment Pharmacol Ther 2019;50(10):1120–1126PubMedPubMedCentralCrossRef

231.

Weinshilboum RM, Sladek SL. Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity. Am J Hum Genet 1980;32(5):651–662PubMedPubMedCentral

232.

Davavala SK, Desai DC, Abraham P, Ashavaid T, Joshi A, Gupta T. Prevalence of TPMT polymorphism in Indian patients requiring immunomodulator therapy and its clinical significance. Indian J Gastroenterol 2014;33(1):41–45PubMedCrossRef

233.

Kumagai K, Hiyama K, Ishioka S, Sato H, Yamanishi Y, McLeod HL, et al. Allelotype frequency of the thiopurine methyltransferase (TPMT) gene in Japanese. Pharmacogenetics 2001;11(3):275–278PubMedCrossRef

234.

Cao Q, Zhu Q, Shang Y, Gao M, Si J. Thiopurine methyltransferase gene polymorphisms in Chinese patients with inflammatory bowel disease. Digestion 2009;79(1):58–63PubMedCrossRef

235.

Takatsu N, Matsui T, Murakami Y, Ishihara H, Hisabe T, Nagahama T, et al. Adverse reactions to azathioprine cannot be predicted by thiopurine S-methyltransferase genotype in Japanese patients with inflammatory bowel disease. J Gastroenterol Hepatol 2009;24(7):1258–1264PubMedCrossRef

236.

Yang SK, Hong M, Baek J, Choi H, Zhao W, Jung Y, et al. A common missense variant in NUDT15 confers susceptibility to thiopurine-induced leukopenia. Nat Genet 2014;46(9):1017–1020PubMedPubMedCentralCrossRef

237.

Chao K, Wang X, Cao Q, Qian J, Wu K, Zhu X, et al. Combined detection of NUDT15 variants could highly predict thiopurine-induced leukopenia in Chinese Patients with inflammatory bowel disease: a multicenter analysis. Inflamm Bowel Dis 2017;23(9):1592–1599PubMedCrossRef

238.

Kim HT, Choi R, Won HH, Choe YH, Kang B, Lee K, et al. NUDT15 genotype distributions in the Korean population. Pharmacogenet Genomics 2017;27(5):197–200PubMedCrossRef

239.

Kuriyama S, Yaegashi N, Nagami F, Arai T, Kawaguchi Y, Osumi N, et al. The Tohoku medical megabank project: design and mission. J Epidemiol 2016;26(9):493–511PubMedCrossRef

240.

Langley PG, Underhill J, Tredger JM, Norris S, McFarlane IG. Thiopurine methyltransferase phenotype and genotype in relation to azathioprine therapy in autoimmune hepatitis. J Hepatol 2002;37(4):441–447PubMedCrossRef

241.

Kakuta Y, Naito T, Onodera M, Kuroha M, Kimura T, Shiga H, et al. NUDT15 R139C causes thiopurine-induced early severe hair loss and leukopenia in Japanese patients with IBD. Pharmacogenomics J 2016;16(3):280–285PubMedCrossRef

242.

Karakoyun M, Ecevit CO, Kilicoglu E, Aydogdu S, Yagci RV, Ozgenc F. Autoimmune hepatitis and long-term disease course in children in Turkey, a single-center experience. Eur J Gastroenterol Hepatol 2016;28(8):927–930PubMedCrossRef

243.

Heneghan MA, Allan ML, Bornstein JD, Muir AJ, Tendler DA. Utility of thiopurine methyltransferase genotyping and phenotyping, and measurement of azathioprine metabolites in the management of patients with autoimmune hepatitis. J Hepatol 2006;45(4):584–591PubMedCrossRef

244.

Johnson PJ, McFarlane IG, Williams R. Azathioprine for long-term maintenance of remission in autoimmune hepatitis. N Engl J Med 1995;333(15):958–963PubMedCrossRef

245.

Lohse AW, Mieli-Vergani G. Autoimmune hepatitis. J Hepatol 2011;55(1):171–182PubMedCrossRef

246.

Pratt DS, Flavin DP, Kaplan MM. The successful treatment of autoimmune hepatitis with 6-mercaptopurine after failure with azathioprine. Gastroenterology 1996;110(1):271–274PubMedCrossRef

247.

Akbari M, Shah S, Velayos FS, Mahadevan U, Cheifetz AS. Systematic review and meta-analysis on the effects of thiopurines on birth outcomes from female and male patients with inflammatory bowel disease. Inflamm Bowel Dis 2013;19(1):15–22PubMedCrossRef

248.

Mack CL, Adams D, Assis DN, Kerkar N, Manns MP, Mayo MJ, et al. Diagnosis and management of autoimmune hepatitis in adults and children: 2019 practice guidance and guidelines from the American association for the study of liver diseases. Hepatology 2020;72(2):671–722PubMedCrossRef

249.

Angelberger S, Reinisch W, Messerschmidt A, Miehsler W, Novacek G, Vogelsang H, et al. Long-term follow-up of babies exposed to azathioprine in utero and via breastfeeding. J Crohns Colitis 2011;5(2):95–100PubMedCrossRef

250.

Miyake Y, Iwasaki Y, Terada R, Okamaoto R, Ikeda H, Makino Y, et al. Persistent elevation of serum alanine aminotransferase levels leads to poor survival and hepatocellular carcinoma development in type 1 autoimmune hepatitis. Aliment Pharmacol Ther 2006;24(8):1197–1205PubMedCrossRef

251.

Hoeroldt B, McFarlane E, Dube A, Basumani P, Karajeh M, Campbell MJ, et al. Long-term outcomes of patients with autoimmune hepatitis managed at a nontransplant center. Gastroenterology 2011;140(7):1980–1989PubMedCrossRef

252.

Hegarty JE, Aria KTN, Portmann B, Eddleston AL, Williams R. Relapse following treatment withdrawal in patients with autoimmune chronic active hepatitis. Hepatology 1983;3(5):685–689PubMedCrossRef

253.

van Gerven NM, Verwer BJ, Witte BI, van Hoek B, Coenraad MJ, van Erpecum KJ, et al. Relapse is almost universal after withdrawal of immunosuppressive medication in patients with autoimmune hepatitis in remission. J Hepatol 2013;58(1):141–147PubMedCrossRef

254.

Czaja AJ. Late relapse of type 1 autoimmune hepatitis after corticosteroid withdrawal. Dig Dis Sci 2010;55(6):1761–1769PubMedCrossRef

255.

Hartl J, Ehlken H, Weiler-Normann C, Sebode M, Kreuels B, Pannicke N, et al. Patient selection based on treatment duration and liver biochemistry increases success rates after treatment withdrawal in autoimmune hepatitis. J Hepatol 2015;62(3):642–646PubMedCrossRef

256.

Montano-Loza AJ, Carpenter HA, Czaja AJ. Improving the end point of corticosteroid therapy in type 1 autoimmune hepatitis to reduce the frequency of relapse. Am J Gastroenterol 2007;102(5):1005–1012PubMedCrossRef

257.

Efe C, Simşek C, Batıbay E, Calışkan AR, Wahlin S. Feasibility of telehealth in the management of autoimmune hepatitis before and during the COVID-19 pandemic. Expert Rev Gastroenterol Hepatol 2020;14(12):1215–1219PubMedCrossRef

258.

Schalm SW, Ammon HV, Summerskill WH. Failure of customary treatment in chronic active liver disease: causes and management. Ann Clin Res 1976;8(3):221–227PubMed

259.

Hindorf U, Jahed K, Bergquist A, Verbaan H, Prytz H, Wallerstedt S, et al. Characterisation and utility of thiopurine methyltransferase and thiopurine metabolite measurements in autoimmune hepatitis. J Hepatol 2010;52(1):106–111PubMedCrossRef

260.

Czaja AJ, Wolf AM, Baggenstoss AH. Laboratory assessment of severe chronic active liver disease during and after corticosteroid therapy: correlation of serum transaminase and gamma globulin levels with histologic features. Gastroenterology 1981;80(4):687–692PubMedCrossRef

261.

Czaja AJ. Safety issues in the management of autoimmune hepatitis. Expert Opin Drug Saf 2008;7(3):319–333PubMedCrossRef

262.

Hennes EM, Oo YH, Schramm C, Denzer U, Buggisch P, Wiegard C, et al. Mycophenolate mofetil as second line therapy in autoimmune hepatitis? Am J Gastroenterol 2008;103(12):3063–3070PubMedCrossRef

263.

Vergani D, Mieli-Vergani G. Pharmacological management of autoimmune hepatitis. Expert Opin Pharmacother 2011;12(4):607–613PubMedCrossRef

264.

Czaja AJ, Menon KV, Carpenter HA. Sustained remission after corticosteroid therapy for type 1 autoimmune hepatitis: a retrospective analysis. Hepatology 2002;35(4):890–897PubMedCrossRef

265.

Duclos-Vallee JC, Ichai P, Samuel D. Autoimmune acute liver failure. Hepatology 2011;54(1):372–373 (author reply 373)PubMedCrossRef

266.

Moenne-Loccoz R, Severac F, Baumert TF, Habersetzer F. Usefulness of corticosteroids as first-line therapy in patients with acute severe autoimmune hepatitis. J Hepatol 2016;65(2):444–446PubMedCrossRef

267.

Zhu B, You SL, Wan ZH, Liu HL, Rong YH, Zang H, et al. Clinical characteristics and corticosteroid therapy in patients with autoimmune-hepatitis-induced liver failure. World J Gastroenterol 2014;20(23):7473–7479PubMedPubMedCentralCrossRef

268.

Ichai P, Duclos-Vallee JC, Guettier C, Hamida SB, Antonini T, Delvart V, et al. Usefulness of corticosteroids for the treatment of severe and fulminant forms of autoimmune hepatitis. Liver Transpl 2007;13(7):996–1003PubMedCrossRef

269.

Czaja AJ. Corticosteroids or not in severe acute or fulminant autoimmune hepatitis: therapeutic brinksmanship and the point beyond salvation. Liver Transpl 2007;13(7):953–955PubMedCrossRef

270.

Miyake Y, Iwasaki Y, Terada R, Onishi T, Okamoto R, Sakai N, et al. Clinical characteristics of fulminant-type autoimmune hepatitis: an analysis of eleven cases. Aliment Pharmacol Ther 2006;23(9):1347–1353PubMedCrossRef

271.

Yeoman AD, Westbrook RH, Zen Y, Maninchedda P, Portmann BC, Devlin J, et al. Early predictors of corticosteroid treatment failure in icteric presentations of autoimmune hepatitis. Hepatology 2011;53(3):926–934PubMedCrossRef

272.

Li YN, Ma H, Zhou L, Zhang J, Guo LP, Li SQ, et al. Autoimmune hepatitis-related cirrhosis: clinical features and effectiveness of immunosuppressive treatment in Chinese patients. Chin Med J (Engl) 2016;129(20):2434–2440CrossRef

273.

Ng TL et al. Immunosuppresive therapy in autoimmune hepatitis in Hong Kong Chinese: 10-year follow-up of a cohort. Hepatol Int 2009;(Suppl):86–220. https://doi.org/10.1007/s12072-009-9123-4

274.

Wang QX, Yan L, Ma X. Autoimmune hepatitis in the Asia–Pacific area. J Clin Transl Hepatol 2018;6(1):48–56PubMedCrossRef

275.

Soares JC, Borgonovo A, Maggi DC, Pasinato AP, Ramos FG, Dantas-Correa EB, et al. Liver dysfunction and fibrosis as predictors of biochemical response to autoimmune hepatitis treatment. Minerva Gastroenterol Dietol 2016;62(2):138–147PubMed

276.

Efe C, Ozaslan E, Kav T, Purnak T, Shorbagi A, Ozkayar O, et al. Liver fibrosis may reduce the efficacy of budesonide in the treatment of autoimmune hepatitis and overlap syndrome. Autoimmun Rev 2012;11(5):330–334PubMedCrossRef

277.

Tansel A, Katz LH, El-Serag HB, Thrift AP, Parepally M, Shakhatreh MH, et al. Incidence and determinants of hepatocellular carcinoma in autoimmune hepatitis: a systematic review and meta-analysis. Clin Gastroenterol Hepatol 2017;15(8):1207-1217.e4PubMedPubMedCentralCrossRef

278.

Westbrook RH, Yeoman AD, Kriese S, Heneghan MA. Outcomes of pregnancy in women with autoimmune hepatitis. J Autoimmun 2012;38(2–3):J239–J244PubMedCrossRef

279.

Terrabuio DR, Abrantes-Lemos CP, Carrilho FJ, Cançado EL. Follow-up of pregnant women with autoimmune hepatitis: the disease behavior along with maternal and fetal outcomes. J Clin Gastroenterol 2009;43(4):350–356PubMedCrossRef

280.

CDC (2017) National birth defects prevention study (NBDPS). https://www.cdc.gov/ncbddd/birthdefects/nbdps.html. Accessed 26 Oct 2020

281.

Buchel E, Van Steenbergen W, Nevens F, Fevery J. Improvement of autoimmune hepatitis during pregnancy followed by flare-up after delivery. Am J Gastroenterol 2002;97(12):3160–3165PubMedCrossRef

282.

Gregorio GV, Portmann B, Karani J, Harrison P, Donaldson PT, Vergani D, et al. Autoimmune hepatitis/sclerosing cholangitis overlap syndrome in childhood: a 16-year prospective study. Hepatology 2001;33(3):544–553PubMedCrossRef

283.

Gregorio GV, Portmann B, Reid F, Donaldson PT, Doherty DG, McCartney M, et al. Autoimmune hepatitis in childhood: a 20-year experience. Hepatology 1997;25(3):541–547PubMedCrossRef

284.

Maggiore G, Veber F, Bernard O, Hadchouel M, Homberg JC, Alvarez F, et al. Autoimmune hepatitis associated with anti-actin antibodies in children and adolescents. J Pediatr Gastroenterol Nutr 1993;17(4):376–381PubMedCrossRef

285.

Schramm C, Kanzler S, zum Buschenfelde KH, Galle PR, Lohse AW. Autoimmune hepatitis in the elderly. Am J Gastroenterol 2001;96(5):1587–1591PubMedCrossRef

286.

Rizvi S, Gawrieh S. Autoimmune hepatitis in the elderly: diagnosis and pharmacologic management. Drugs Aging 2018;35(7):589–602PubMedCrossRef

287.

De Lemos-Bonotto M, Valle-Tovo C, Costabeber AM, Mattos AA, Azeredo-da-Silva ALF. A systematic review and meta-analysis of second-line immunosuppressants for autoimmune hepatitis treatment. Eur J Gastroenterol Hepatol 2018;30(2):212–216PubMedCrossRef

288.

Zandieh I, Krygier D, Wong V, Howard J, Worobetz L, Minuk G, et al. The use of budesonide in the treatment of autoimmune hepatitis in Canada. Can J Gastroenterol 2008;22(4):388–392PubMedPubMedCentralCrossRef

289.

Hempfling W, Grunhage F, Dilger K, Reichel C, Beuers U, Sauerbruch T. Pharmacokinetics and pharmacodynamic action of budesonide in early- and late-stage primary biliary cirrhosis. Hepatology 2003;38(1):196–202PubMedCrossRef

290.

Csepregi A, Rocken C, Treiber G, Malfertheiner P. Budesonide induces complete remission in autoimmune hepatitis. World J Gastroenterol 2006;12(9):1362–1366PubMedPubMedCentralCrossRef

291.

Manns MP, Woynarowski M, Kreisel W, Lurie Y, Rust C, Zuckerman E, et al. Budesonide induces remission more effectively than prednisone in a controlled trial of patients with autoimmune hepatitis. Gastroenterology 2010;139(4):1198–1206PubMedCrossRef

292.

Czaja AJ. Current and future treatments of autoimmune hepatitis. Expert Rev Gastroenterol Hepatol 2009;3(3):269–291PubMedCrossRef

293.

Czaja AJ. Promising pharmacological, molecular and cellular treatments of autoimmune hepatitis. Curr Pharm Des 2011;17(29):3120–3140PubMedCrossRef

294.

De Maeyer F, Lapauw B, Hoorens A, Geerts A, Van Vlierberghe H, Verhelst X. Secondary adrenal insufficiency after treatment with budesonide for autoimmune hepatitis. Case Rep Gastroenterol 2018;12(3):597–601PubMedPubMedCentralCrossRef

295.

Lu FB, Hu ED, Xu LM, Hu YB, Chen L, Wu JL, et al. Comparative efficacy and tolerability of treatments for adult autoimmune hepatitis: a systematic review and network meta-analysis. Exp Ther Med 2018;15(6):4838–4850PubMedPubMedCentral

296.

Czaja AJ, Lindor KD. Failure of budesonide in a pilot study of treatment-dependent autoimmune hepatitis. Gastroenterology 2000;119(5):1312–1316PubMedCrossRef

297.

Zachou K, Gatselis NK, Arvaniti P, Gabeta S, Rigopoulou EI, Koukoulis GK, et al. A real-world study focused on the long-term efficacy of mycophenolate mofetil as first-line treatment of autoimmune hepatitis. Aliment Pharmacol Ther 2016;43(10):1035–1047PubMedCrossRef

298.

Zolfino T, Heneghan MA, Norris S, Harrison PM, Portmann BC, McFarlane IG. Characteristics of autoimmune hepatitis in patients who are not of European Caucasoid ethnic origin. Gut 2002;50(5):713–717PubMedPubMedCentralCrossRef

299.

Chatur N, Ramji A, Bain VG, Ma MM, Marotta PJ, Ghent CN, et al. Transplant immunosuppressive agents in non-transplant chronic autoimmune hepatitis: the Canadian association for the study of liver (CASL) experience with mycophenolate mofetil and tacrolimus. Liver Int 2005;25(4):723–727PubMedCrossRef

300.

Jothimani D, Cramp ME, Cross TJ. Role of mycophenolate mofetil for the treatment of autoimmune hepatitis-an observational study. J Clin Exp Hepatol 2014;4(3):221–225PubMedPubMedCentralCrossRef

301.

Zachou K, Gatselis N, Papadamou G, Rigopoulou EI, Dalekos GN. Mycophenolate for the treatment of autoimmune hepatitis: prospective assessment of its efficacy and safety for induction and maintenance of remission in a large cohort of treatment-naive patients. J Hepatol 2011;55(3):636–646PubMedCrossRef

302.

Giannakopoulos G, Verbaan H, Friis-Liby IL, Sangfelt P, Nyhlin N, Almer S. Mycophenolate mofetil treatment in patients with autoimmune hepatitis failing standard therapy with prednisolone and azathioprine. Dig Liver Dis 2019;51(2):253–257PubMedCrossRef

303.

Roberts SK, Lim R, Strasser S, Nicoll A, Gazzola A, Mitchell J, et al. Efficacy and safety of mycophenolate mofetil in patients with autoimmune hepatitis and suboptimal outcomes after standard therapy. Clin Gastroenterol Hepatol 2018;16(2):268–277PubMedCrossRef

304.

Efe C, Hagstrom H, Ytting H, Bhanji RA, Muller NF, Wang Q, et al. Efficacy and safety of mycophenolate mofetil and tacrolimus as second-line therapy for patients with autoimmune hepatitis. Clin Gastroenterol Hepatol 2017;15(12):1950-1956.e1PubMedCrossRef

305.

Nasseri-Moghaddam S, Nikfam S, Karimian S, Khashayar P, Malekzadeh R. Cyclosporine-A versus prednisolone for induction of remission in auto-immune hepatitis: interim analysis report of a randomized controlled trial. Middle East J Dig Dis 2013;5(4):193–200PubMedPubMedCentral

306.

Hanouneh M, Ritchie MM, Ascha M, Ascha MS, Chedid A, Sanguankeo A, et al. A review of the utility of tacrolimus in the management of adults with autoimmune hepatitis. Scand J Gastroenterol 2019;54(1):76–80. https://doi.org/10.1080/00365521.2018.1551498.CrossRef

307.

Than NN, Wiegard C, Weiler-Normann C, Fussel K, Mann J, Hodson J, et al. Long-term follow-up of patients with difficult to treat type 1 autoimmune hepatitis on tacrolimus therapy. Scand J Gastroenterol 2016;51(3):329–336PubMedCrossRef

308.

Hubener S, Oo YH, Than NN, Hubener P, Weiler-Normann C, Lohse AW, et al. Efficacy of 6-mercaptopurine as second-line treatment for patients with autoimmune hepatitis and azathioprine intolerance. Clin Gastroenterol Hepatol 2016;14(3):445–453PubMedCrossRef

309.

de Boer NK, van Nieuwkerk CM, Pages MNA, de Boer SY, Derijks LJ, Mulder CJ. Promising treatment of autoimmune hepatitis with 6-thioguanine after adverse events on azathioprine. Eur J Gastroenterol Hepatol 2005;17(4):457–461PubMedCrossRef

310.

Pavanello F, Zucca E, Ghielmini M. Rituximab: 13 open questions after 20 years of clinical use. Cancer Treat Rev 2017;53:38–46PubMedCrossRef

311.

Weiler-Normann C, Schramm C, Quaas A, Wiegard C, Glaubke C, Pannicke N, et al. Infliximab as a rescue treatment in difficult-to-treat autoimmune hepatitis. J Hepatol 2013;58(3):529–534PubMedCrossRef

312.

Efe C. Drug induced autoimmune hepatitis and TNF-α blocking agents: is there a real relationship? Autoimmun Rev 2013;12(3):337–339PubMedCrossRef

313.

Kerkar N, Dugan C, Rumbo C, Morotti RA, Gondolesi G, Shneider BL, et al. Rapamycin successfully treats post-transplant autoimmune hepatitis. Am J Transplant 2005;5(5):1085–1089PubMedCrossRef

314.

Chatrath H, Allen L, Boyer TD. Use of sirolimus in the treatment of refractory autoimmune hepatitis. Am J Med 2014;127(11):1128–1131PubMedCrossRef

315.

Kanzler S, Gerken G, Dienes HP, zum Buschenfelde KHM, Lohse AW. Cyclophosphamide as alternative immunosuppressive therapy for autoimmune hepatitis–report of three cases. Z Gastroenterol 1997;35(7):571–578PubMed

316.

Burak KW, Urbanski SJ, Swain MG. Successful treatment of refractory type 1 autoimmune hepatitis with methotrexate. J Hepatol 1998;29(6):990–993PubMedCrossRef

317.

van den Brand FF, van Nieuwkerk CMJ, Verwer BJ, de Boer YS, de Boer NKH, Mulder CJJ, et al. Biochemical efficacy of tioguanine in autoimmune hepatitis: a retrospective review of practice in the Netherlands. Aliment Pharmacol Ther 2018;48(7):761–767PubMedPubMedCentralCrossRef

318.

Burak KW, Swain MG, Santodomingo-Garzon T, Lee SS, Urbanski SJ, Aspinall AI, et al. Rituximab for the treatment of patients with autoimmune hepatitis who are refractory or intolerant to standard therapy. Can J Gastroenterol 2013;27(5):273–280PubMedPubMedCentralCrossRef

319.

Adam R, Karam V, Delvart V, O’Grady J, Mirza D, Klempnauer J, et al. Evolution of indications and results of liver transplantation in Europe. A report from the European liver transplant registry (ELTR). J Hepatol 2012;57(3):675–688PubMedCrossRef

320.

Singal AK, Guturu P, Hmoud B, Kuo YF, Salameh H, Wiesner RH. Evolving frequency and outcomes of liver transplantation based on etiology of liver disease. Transplantation 2013;95(5):755–760PubMedCrossRef

321.

TJLT Society. Liver transplantation in Japan- registry by the Japanese liver transplantation society- [in Japanese]. Ishoku 2015;52(2–3):134–147

322.

Ayata G, Gordon FD, Lewis WD, Pomfret E, Pomposelli JJ, Jenkins RL, et al. Liver transplantation for autoimmune hepatitis: a long-term pathologic study. Hepatology 2000;32(2):185–192PubMedCrossRef

323.

Campsen J, Zimmerman MA, Trotter JF, Wachs M, Bak T, Steinberg T, et al. Liver transplantation for autoimmune hepatitis and the success of aggressive corticosteroid withdrawal. Liver Transpl 2008;14(9):1281–1286PubMedCrossRef

324.

Duclos-Vallee JC, Sebagh M, Rifai K, Johanet C, Ballot E, Guettier C, et al. A 10 year follow up study of patients transplanted for autoimmune hepatitis: histological recurrence precedes clinical and biochemical recurrence. Gut 2003;52(6):893–897PubMedPubMedCentralCrossRef

325.

Gonzalez-Koch A, Czaja AJ, Carpenter HA, Roberts SK, Charlton MR, Porayko MK, et al. Recurrent autoimmune hepatitis after orthotopic liver transplantation. Liver Transpl 2001;7(4):302–310PubMedCrossRef

326.

Krishnamoorthy TL, Miezynska-Kurtycz J, Hodson J, Gunson BK, Neuberger J, Milkiewicz P, et al. Longterm corticosteroid use after liver transplantation for autoimmune hepatitis is safe and associated with a lower incidence of recurrent disease. Liver Transpl 2016;22(1):34–41PubMedCrossRef

327.

Milkiewicz P, Hubscher SG, Skiba G, Hathaway M, Elias E. Recurrence of autoimmune hepatitis after liver transplantation. Transplantation 1999;68(2):253–256PubMedCrossRef

328.

Molmenti EP, Netto GJ, Murray NG, Smith DM, Molmenti H, Crippin JS, et al. Incidence and recurrence of autoimmune/alloimmune hepatitis in liver transplant recipients. Liver Transpl 2002;8(6):519–526PubMedCrossRef

329.

Montano-Loza AJ, Mason AL, Ma M, Bastiampillai RJ, Bain VG, Tandon P. Risk factors for recurrence of autoimmune hepatitis after liver transplantation. Liver Transpl 2009;15(10):1254–1261PubMedCrossRef

330.

Prados E, Cuervas-Mons V, de la Mata M, Fraga E, Rimola A, Prieto M, et al. Outcome of autoimmune hepatitis after liver transplantation. Transplantation 1998;66(12):1645–1650PubMedCrossRef

331.

Ratziu V, Samuel D, Sebagh M, Farges O, Saliba F, Ichai P, et al. Long-term follow-up after liver transplantation for autoimmune hepatitis: evidence of recurrence of primary disease. J Hepatol 1999;30(1):131–141PubMedCrossRef

332.

Reich DJ, Fiel I, Guarrera JV, Emre S, Guy SR, Schwartz ME, et al. Liver transplantation for autoimmune hepatitis. Hepatology 2000;32(4 Pt 1):693–700PubMedCrossRef

333.

Montano-Loza AJ, Bhanji RA, Wasilenko S, Mason AL. Systematic review: recurrent autoimmune liver diseases after liver transplantation. Aliment Pharmacol Ther 2017;45(4):485–500PubMedCrossRef

334.

Visseren T, Murad SD. Recurrence of primary sclerosing cholangitis, primary biliary cholangitis and auto-immune hepatitis after liver transplantation. Best Pract Res Clin Gastroenterol 2017;31(2):187–198PubMedCrossRef

335.

Alvarez F, Berg P, Bianchi F, Bianchi L, Burroughs A, Cancado E, et al. International autoimmune hepatitis group report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol 1999;31:929–938PubMedCrossRef

336.

Balan V, Ruppert K, Demetris AJ, Ledneva T, Duquesnoy RJ, Detre KM, et al. Long-term outcome of human leukocyte antigen mismatching in liver transplantation: results of the national institute of diabetes and digestive and kidney diseases liver transplantation database. Hepatology 2008;48(3):878–888PubMedCrossRef

337.

Kerkar N, Vergani D. De novo autoimmune hepatitis- is this different in adults compared to children? J Autoimmun 2018;95:26–33PubMedCrossRef

338.

Kerkar N, Yanni G. ‘De novo’ and ‘recurrent’ autoimmune hepatitis after liver transplantation: a comprehensive review. J Autoimmun 2016;66:17–24PubMedCrossRef

339.

Montano-Loza AJ, Vargas-Vorackova F, Ma M, Bain VG, Burak K, Kumar T, et al. Incidence and risk factors associated with de novo autoimmune hepatitis after liver transplantation. Liver Int 2012;32(9):1426–1433PubMedCrossRef

340.

Gupta P, Hart J, Millis JM, Cronin D, Brady L. De novo hepatitis with autoimmune antibodies and atypical histology: a rare cause of late graft dysfunction after pediatric liver transplantation. Transplantation 2001;71(5):664–668PubMedCrossRef

341.

Pongpaibul A, Venick RS, McDiarmid SV, Lassman CR. Histopathology of de novo autoimmune hepatitis. Liver Transpl 2012;18(7):811–818PubMedCrossRef

342.

Czaja AJ. Diagnosis, pathogenesis, and treatment of autoimmune hepatitis after liver transplantation. Dig Dis Sci 2012;57(9):2248–2266PubMedCrossRef

343.

Lindor KD, Gershwin ME, Poupon R, Kaplan M, Bergasa NV, Heathcote EJ. Primary biliary cirrhosis. Hepatology 2009;50(1):291–308PubMedCrossRef

344.

Chazouilleres O, Wendum D, Serfaty L, Rosmorduc O, Poupon R. Long term outcome and response to therapy of primary biliary cirrhosis-autoimmune hepatitis overlap syndrome. J Hepatol 2006;44(2):400–406PubMedCrossRef

345.

Ozaslan E, Efe C, Heurgué-Berlot A, Kav T, Masi C, Purnak T, et al. Factors associated with response to therapy and outcome of patients with primary biliary cirrhosis with features of autoimmune hepatitis. Clin Gastroenterol Hepatol 2014;12(5):863–869PubMedCrossRef

346.

Czaja AJ. Diagnosis and management of the overlap syndromes of autoimmune hepatitis. Can J Gastroenterol 2013;27(7):417–423PubMedPubMedCentralCrossRef

347.

Floreani A, Rizzotto ER, Ferrara F, Carderi I, Caroli D, Blasone L, et al. Clinical course and outcome of autoimmune hepatitis/primary sclerosing cholangitis overlap syndrome. Am J Gastroenterol 2005;100(7):1516–1522PubMedCrossRef

348.

Al-Chalabi T, Portmann BC, Bernal W, McFarlane IG, Heneghan MA. Autoimmune hepatitis overlap syndromes: an evaluation of treatment response, long-term outcome and survival. Aliment Pharmacol Ther 2008;28(2):209–220PubMedCrossRef

349.

Olsson R, Glaumann H, Almer S, Broome U, Lebrun B, Bergquist A, et al. High prevalence of small duct primary sclerosing cholangitis among patients with overlapping autoimmune hepatitis and primary sclerosing cholangitis. Eur J Intern Med 2009;20(2):190–196PubMedCrossRef

350.

Castiella A, Zapata E, Lucena MI, Andrade RJ. Drug-induced autoimmune liver disease: a diagnostic dilemma of an increasingly reported disease. World J Hepatol 2014;6(4):160–168PubMedPubMedCentralCrossRef

351.

Weber S, Benesic A, Rotter I, Gerbes AL. Early ALT response to corticosteroid treatment distinguishes idiosyncratic drug-induced liver injury from autoimmune hepatitis. Liver Int 2019;39(10):1906–1917PubMedCrossRef

352.

Björnsson E, Talwalkar J, Treeprasertsuk S, Kamath PS, Takahashi N, Sanderson S, et al. Drug-induced autoimmune hepatitis: clinical characteristics and prognosis. Hepatology 2010;51(6):2040–2048PubMedCrossRef

353.

Terrault NA, Lok ASF, McMahon BJ, Chang KM, Hwang JP, Jonas MM, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology 2018;67(4):1560–1599PubMedCrossRef

354.

EASL. EASL recommendations on treatment of hepatitis C 2018. J Hepatol 2018;69(2):461–511CrossRef

355.

De Luca-Johnson J, Wangensteen KJ, Hanson J, Krawitt E, Wilcox R. Natural history of patients presenting with autoimmune hepatitis and coincident nonalcoholic fatty liver disease. Dig Dis Sci 2016;61(9):2710–2720PubMedPubMedCentralCrossRef

356.

Komura T, Ohta H, Seike T, Shimizu Y, Nakai R, Omura H, et al. The efficacy of corticosteroid therapy in a patient with non-alcoholic steatohepatitis overlapping autoimmune hepatitis. Intern Med 2018;57(6):807–812PubMedCrossRef

357.

Wan DW, Marks K, Yantiss RK, Talal AH. Autoimmune hepatitis in the HIV-infected patient: a therapeutic dilemma. AIDS Patient Care STDS 2009;23(6):407–413PubMedCrossRef

358.

359.

Valean S, Acalovschi M, Dumitrascu DL, Ciobanu L, Nagy G, Chira R. Hepatocellular carcinoma in patients with autoimmune hepatitis—a systematic review of the literature published between 1989–2016. Med Pharm Rep 2019;92(2):99–105PubMedPubMedCentral

360.

Hino-Arinaga T, Ide T, Kuromatsu R, Miyajima I, Ogata K, Kuwahara R, et al. Risk factors for hepatocellular carcinoma in Japanese patients with autoimmune hepatitis type 1. J Gastroenterol 2012;47(5):569–576PubMedCrossRef

361.

Migita K, Watanabe Y, Jiuchi Y, Nakamura Y, Saito A, Yagura M, et al. Hepatocellular carcinoma and survival in patients with autoimmune hepatitis (Japanese national hospital organization-autoimmune hepatitis prospective study). Liver Int 2012;32(5):837–844PubMedCrossRef

362.

Montano-Loza AJ, Carpenter HA, Czaja AJ. Predictive factors for hepatocellular carcinoma in type 1 autoimmune hepatitis. Am J Gastroenterol 2008;103(8):1944–1951PubMedCrossRef

363.

Teufel A, Weinmann A, Centner C, Piendl A, Lohse AW, Galle PR, et al. Hepatocellular carcinoma in patients with autoimmune hepatitis. World J Gastroenterol 2009;15(5):578–582PubMedPubMedCentralCrossRef

364.

Wong RJ, Gish R, Frederick T, Bzowej N, Frenette C. Development of hepatocellular carcinoma in autoimmune hepatitis patients: a case series. Dig Dis Sci 2011;56(2):578–585PubMedCrossRef

365.

Borssen AD, Almer S, Prytz H, Wallerstedt S, Friis-Liby IL, Bergquist A, et al. Hepatocellular and extrahepatic cancer in patients with autoimmune hepatitis—a long-term follow-up study in 634 Swedish patients. Scand J Gastroenterol 2015;50(2):217–223CrossRef

366.

Dakhoul L, Jones KR, Gawrieh S, Ghabril M, McShane C, Vuppalanchi R, et al. Older age and disease duration are highly associated with hepatocellular carcinoma in patients with autoimmune hepatitis. Dig Dis Sci 2019;64(6):1705–1710. https://doi.org/10.1007/s10620-018-5441-5.PubMedPubMedCentralCrossRef

367.

Ohira H, Abe K, Takahashi A, Zeniya M, Ichida T. Clinical features of hepatocellular carcinoma in patients with autoimmune hepatitis in Japan. J Gastroenterol 2013;48(1):109–114PubMedCrossRef

Title: The Asian Pacific Association for the Study of the Liver clinical practice guidance: the diagnosis and management of patients with autoimmune hepatitis
Authors: Guiqiang Wang
Atsushi Tanaka
Hong Zhao
Jidong Jia
Xiong Ma
Kenichi Harada
Fu-Sheng Wang
Lai Wei
Qixia Wang
Ying Sun
Yuan Hong
Huiying Rao
Cumali Efe
George Lau
Diana Payawal
Rino Gani
Keith Lindor
Wasim Jafri
Masao Omata
Shiv Kumar Sarin
Publication date: 01-04-2021
Publisher: Springer India
Keywords: Azathioprine
Autoimmune Hepatitis
Azathioprine
Published in: Hepatology International / Issue 2/2021
Print ISSN: 1936-0533
Electronic ISSN: 1936-0541
DOI: https://doi.org/10.1007/s12072-021-10170-1

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

Illustration of figure on mountain summit/© Orapun / Stock.adobe.com, STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

At a glance: The STEP trials

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 2/2021

Sofosbuvir/velpatasvir for patients with chronic hepatitis C virus infection and compensated liver disease: real-world data in Taiwan

Liver injury predicts overall mortality in severe COVID-19: a prospective multicenter study in Brazil

Liver fibrosis scores and coronary atherosclerosis: novel findings in patients with stable coronary artery disease

The prevalence of occult HBV infection in immunized children with HBs Ag positive parents: a hospital based analysis

Combining end-of-treatment HBsAg and baseline hepatitis B core-related antigen reduce HBV relapse rate after tenofovir cessation

A novel evidence of serial changes of bone mineral density in chronic hepatitis B patients treated with entecavir

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage